Fresenius Medical Care AG & Co. KGaA
Pharmaceutical Companies · Hochtaunuskreis
Fresenius Medical Care AG & Co. KGaA is a pharmaceutical company based in Hochtaunuskreis, Germany.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Fresenius Medical Care AG & Co. KGaA Address & Contact
Company profile
1996
Founded
130.000+
Employees
Fresenius Medical Care AG & Co. KGaA Overview
Fresenius Medical Care AG & Co. KGaA (FMC) is the world's largest provider of products and services for people with chronic kidney failure. The company is headquartered in Bad Homburg vor der Höhe (Hochtaunuskreis, Hesse) and is a subsidiary of Fresenius SE & Co. KGaA. FMC is listed on the Frankfurt Stock Exchange (MDAX) and the New York Stock Exchange (NYSE). Worldwide, Fresenius Medical Care employs approximately 130,000 people and operates over 4,000 dialysis centers in more than 40 countries. The company achieved a revenue of 19 billion euros in 2022, highlighting FMC’s significant economic role in the healthcare sector.
Field of Activity & Products
The core business of Fresenius Medical Care encompasses two central areas: First, the manufacturing and distribution of dialysis machines, dialyzers (kidney filters), dialysis concentrates, and related consumables. Second, the operation of a global network of outpatient and inpatient dialysis centers. FMC’s product brands include clinically proven machines such as the 5008 system and the 6008 system, as well as state-of-the-art dialyzers from the Helixone and FX classes. FMC provides care for approximately 340,000 dialysis patients in its centers worldwide, supplies products to hundreds of thousands of additional patients, and accounts for more than 60% of outpatient dialysis needs in the USA. In Germany, FMC is one of the largest operators of outpatient dialysis practices, with a market share of over 30%. Notably, innovative therapy concepts that are supported by evidence-based research stand out.
Regulatory Classification and Quality Standards
Fresenius Medical Care is subject to strict regulatory oversight to ensure that all products and services meet the highest quality standards. This regulation is carried out by various national and international authorities, including the Federal Institute for Drugs and Medical Devices (BfArM) in Germany and the Food and Drug Administration (FDA) in the USA. The company holds numerous ISO and GMP certifications that guarantee the quality and safety of its products. In addition to product-related regulation, internal quality management systems and continuous improvement processes place great emphasis on efficiency as well as patient and employee safety. Fresenius Medical Care has also increasingly focused on digital solutions in recent years to improve patient care and operational efficiency.
History & Structure
Fresenius Medical Care was formed in 1996 from the merger of Fresenius AG (Germany) with National Medical Care (USA). The German location in Bad Homburg houses the global headquarters and essential management functions, where strategic decisions for worldwide operations are made. In 2023, the company was reorganized as part of a comprehensive restructuring program to increase profitability and reduce costs. This multifaceted reorganization aims to secure the company's innovation capacity and market position in the long term. A particular focus is placed on expansion into emerging markets, where the demand for high-quality dialysis services is growing, especially due to the increasing incidence of chronic kidney diseases.
Regional Importance and Social Responsibility
Fresenius Medical Care not only plays a highly important role in the healthcare sector but also contributes to the regional economy in Hochtaunuskreis and beyond. By creating jobs and collaborating with local suppliers, the company provides significant economic impulses. Additionally, FMC actively engages in social projects that address access to medical care, particularly in underserved regions. The company promotes programs aimed at raising awareness about chronic kidney diseases and supports initiatives that help patients and their families cope with these life-changing diagnoses.
More information: Pharmaceutical companies in Hesse or all pharmaceutical companies in Germany on Sanoliste.
Frequently asked questions about Fresenius Medical Care AG & Co. KGaA
What does Fresenius Medical Care do?
Fresenius Medical Care AG & Co. KGaA offers products and Dienstleisungen for patients with chronischen Nierenleiden. Sie stellt Dialysegeräte, Dialysatoren and Zubehör her and betreut weltweit Dialyse-patients in Dialyse-Kliniken.
More Pharmaceutical Companies in Hochtaunuskreis
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.